UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer

Science translational medicine, 2015-04, Vol.7 (283), p.283ra51

2015

Volltextzugriff (PDF)

PI3K pathway inhibitors: better not left alone

Current pharmaceutical design, 2013-02, Vol.19 (5), p.895-906

2013

Volltextzugriff (PDF)

Demonstrating the impact of POLST forms on hospital care requires information not contained in state registries

PloS one, 2019-06, Vol.14 (6), p.e0217113-e0217113

2019

Volltextzugriff (PDF)

Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer

Science signaling, 2014-03, Vol.7 (318), p.ra29

2014

Volltextzugriff (PDF)

Long term side effects of adjuvant chemotherapy in patients with early breast cancer

Breast (Edinburgh), 2015-11, Vol.24 (2), p.S149-S153

2015

Volltextzugriff (PDF)

Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology

Annual review of medicine, 2018-01, Vol.69 (1), p.319-331

2018

Volltextzugriff (PDF)

ALK Fusions in Renal Cell Carcinoma: Response to Entrectinib

JCO precision oncology, 2018-11 (2), p.1-8

2018

Volltextzugriff (PDF)

First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors

Clinical cancer research, 2019-09, Vol.25 (18), p.5458-5465

2019

Volltextzugriff (PDF)

Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets

Clinical cancer research, 2024-09, Vol.30 (17), p.3812-3823

2024

Volltextzugriff (PDF)

Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study

Journal of clinical oncology, 2024-09

2024

Volltextzugriff (PDF)

High Frequency of SDHB Germline Mutations in Patients with Malignant Catecholamine-Producing Paragangliomas: Implications for Genetic Testing

The journal of clinical endocrinology and metabolism, 2006-11, Vol.91 (11), p.4505-4509

2006

Volltextzugriff (PDF)

Learning All That We Can From MyPathway

Journal of clinical oncology, 2018-08, Vol.36 (23), p.2450-2451

2018

Volltextzugriff (PDF)

Management of Breast Cancer During the COVID-19 Pandemic: A Stage- and Subtype-Specific Approach

JCO oncology practice, 2020-10, Vol.16 (10), p.665-674

2020

Volltextzugriff (PDF)

Poly (ADP-ribose) Polymerase Inhibitor Resistance Driven by Emergence of Polyclonal Mutations With Convergent Evolution: A Molecular Tumor Board Discussion

JCO precision oncology, 2024-10, Vol.8 (8), p.e2400254

2024

Volltextzugriff (PDF)

Real-World Outcomes of an Automated Physician Support System for Genome-Driven Oncology

JCO precision oncology, 2019-07 (3), p.1-13

2019

Volltextzugriff (PDF)

Abstract CT011: First in human study of activin-A inhibitor, STM434, in patients with granulosa cell ovarian cancer and other advanced solid tumors

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.CT011-CT011

2018

Volltextzugriff (PDF)

PI3K Pathway Inhibitors: Better Not Left Alone

Current pharmaceutical design, 2012-12, Vol.19 (5), p.895-906

2012

Volltextzugriff (PDF)

Abstract P3-01-07: Phase II trial of palbociclib with fulvestrant in individuals with hormone receptor-positive, HER2-negative metastatic breast cancer with disease progression after palbociclib with an aromatase inhibitor

Cancer research (Chicago, Ill.), 2023-03, Vol.83 (5_Supplement), p.P3-P3-01-07

2023

Volltextzugriff (PDF)

Abstract PD13-12: PD13-12 Imlunestrant, an oral selective estrogen receptor degrader, in combination with abemaciclib with or without an aromatase inhibitor, in estrogen receptor-positive advanced breast cancer: Results from the phase 1a/b EMBER study

Cancer research (Chicago, Ill.), 2023-03, Vol.83 (5_Supplement), p.PD13-12-PD13-12

2023

Volltextzugriff (PDF)

Gut mucosal virome alterations in ulcerative colitis

Gut, 2019-07, Vol.68 (7), p.1169-1179

2019

Volltextzugriff (PDF)

Hydrogen sulfide cytoprotective signaling is endothelial nitric oxide synthase-nitric oxide dependent

Proceedings of the National Academy of Sciences - PNAS, 2014-02, Vol.111 (8), p.3182-3187

2014

Volltextzugriff (PDF)

Carbon-based quantum dots for fluorescence imaging of cells and tissues

RSC advances, 2014, Vol.4 (21), p.10791

2014

Volltextzugriff (PDF)

Gut fungal dysbiosis correlates with reduced efficacy of fecal microbiota transplantation in Clostridium difficile infection

Nature communications, 2018-09, Vol.9 (1), p.3663-11, Article 3663

2018

Volltextzugriff (PDF)

Gut Dysbiosis Is Linked to Hypertension

Hypertension (Dallas, Tex. 1979), 2015-06, Vol.65 (6), p.1331-1340

2015

Volltextzugriff (PDF)

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia

The New England journal of medicine, 2020-03, Vol.382 (13), p.1199-1207

2020

Volltextzugriff (PDF)

1 – 25 von 178

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(173)
Mit Volltextzugriff
(159)

Publikationsform

Sprache

Englisch
(177)

Erscheinungsjahr

n.n

Thema

Science & Technology
(130)
Life Sciences & Biomedicine
(99)
Humans
(83)
Female
(41)
Animals
(34)
Male
(33)
Mice
(21)
Oncology
(20)
Adult
(19)
Middle Aged
(18)
Multidisciplinary Sciences
(17)
Science & Technology - Other Topics
(17)
Cell Biology
(16)
Proteins
(16)
Adolescent
(15)
Aged
(12)
Child
(12)
Covid-19
(12)
Mutation
(12)
Physical Sciences
(11)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer

PI3K pathway inhibitors: better not left alone

Demonstrating the impact of POLST forms on hospital care requires information not contained in state registries

Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer

Long term side effects of adjuvant chemotherapy in patients with early breast cancer

Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology

ALK Fusions in Renal Cell Carcinoma: Response to Entrectinib

First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors

Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets

Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study

High Frequency of SDHB Germline Mutations in Patients with Malignant Catecholamine-Producing Paragangliomas: Implications for Genetic Testing

Learning All That We Can From MyPathway

Management of Breast Cancer During the COVID-19 Pandemic: A Stage- and Subtype-Specific Approach

Poly (ADP-ribose) Polymerase Inhibitor Resistance Driven by Emergence of Polyclonal Mutations With Convergent Evolution: A Molecular Tumor Board Discussion

Real-World Outcomes of an Automated Physician Support System for Genome-Driven Oncology

Abstract CT011: First in human study of activin-A inhibitor, STM434, in patients with granulosa cell ovarian cancer and other advanced solid tumors

PI3K Pathway Inhibitors: Better Not Left Alone

Abstract P3-01-07: Phase II trial of palbociclib with fulvestrant in individuals with hormone receptor-positive, HER2-negative metastatic breast cancer with disease progression after palbociclib with an aromatase inhibitor

Abstract PD13-12: PD13-12 Imlunestrant, an oral selective estrogen receptor degrader, in combination with abemaciclib with or without an aromatase inhibitor, in estrogen receptor-positive advanced breast cancer: Results from the phase 1a/b EMBER study

Gut mucosal virome alterations in ulcerative colitis

Hydrogen sulfide cytoprotective signaling is endothelial nitric oxide synthase-nitric oxide dependent

Carbon-based quantum dots for fluorescence imaging of cells and tissues

Gut fungal dysbiosis correlates with reduced efficacy of fecal microbiota transplantation in Clostridium difficile infection

Gut Dysbiosis Is Linked to Hypertension

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia

Suchergebnisse filtern